Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics CHATHAM, N.J.

Tonix Pharmaceuticals Holding Corp. 8-K

Tonix Pharmaceuticals Announces Appointment of Jeffrey

Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics

CHATHAM, N.J., March 9, 2022 (GLOBE NEWSWIRE)

-- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced

the appointment of Jeffrey Rosenfeld, Ph.D., as its new Executive Director, Genomics and Bioinformatics. In this role, Dr. Rosenfeld will

direct Tonix's pharmacogenomics efforts including applying artificial intelligence, genome-wide association studies and mathematical

modeling techniques to the analysis of patient outcomes in Tonix's clinical trials.

"Dr. Rosenfeld brings substantial genomics

expertise to Tonix that will support our efforts in pharmacogenomics and companion diagnostics," said Seth Lederman, M.D., Chief

Executive Officer of Tonix Pharmaceuticals. "As we continue to advance our pipeline and programs, Dr. Rosenfeld's abilities

and his passion for genomics will support the future success of our drug development efforts."

"I am excited to join Tonix to lead the

Company's efforts to integrate genomics with clinical trials," said Dr. Rosenfeld. "I look forward to working closely with

the team to fully realize the potential of the Company's deep portfolio of product candidates."

Dr. Rosenfeld has a record of achievement in

genomics and bioinformatics. Over his 15-year career in genomics, he has contributed to a wide range of biological and genetic projects,

including genetic association studies of schizophrenia and clinical cancer genome sequencing. Most recently, he led an effort to investigate

markers for autism in paternal sperm. For the past seven years, Dr. Rosenfeld has been an Assistant Professor of Pathology and Laboratory

Medicine and the Manager of the Biomedical Informatics Shared Resource at the Rutgers Cancer Institute of New Jersey. In 2013, he founded

Genome Liberty which developed tools for direct-to-consumer pharmacogenomics testing. Dr. Rosenfeld earned his B.S. in Biology and M.S.

in Biotechnology from the University of Pennsylvania and a Ph.D. in Biology from New York University. He completed doctoral research at

the Cold Spring Harbor Laboratory.

About Tonix Pharmaceuticals Holding Corp.

Tonix is a clinical-stage biopharmaceutical

company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and

alleviate suffering. Tonix's portfolio is composed of immunology, central nervous system (CNS) and infectious disease product candidates.

Tonix's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including Tonix's

lead immunology candidate TNX-15001, which is a humanized monoclonal antibody targeting CD40 ligand being developed for the

prevention of allograft rejection and the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to start in the second

half of 2022. The Company's CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and

addiction conditions. Tonix's lead CNS candidate, TNX-102 SL2, (cyclobenzaprine HCl sublingual tablets), is a small molecule

drug in mid-Phase 3 development for the management of fibromyalgia, with a new Phase 3 study expected to start in the first half of 2022.

TNX-102 SL is also being developed to treat Long COVID, a chronic post-COVID-19 condition. Tonix expects to initiate a Phase 2 study in

Long COVID in the first half of 2022. TNX-13003 is a biologic designed to treat cocaine intoxication that is expected to start

a Phase 2 trial in the first half of 2022. Tonix's infectious disease pipeline includes a vaccine in development to prevent smallpox,

next-generation vaccines to prevent COVID-19 and an antiviral to treat COVID-19. Tonix's lead vaccine program is TNX-801 (live horsepox

virus for percutaneous administration) for preventing smallpox and monkeypox4. Horsepox is also the basis for Tonix's

recombinant pox vaccine (RPV) platform. Tonix's lead vaccine candidates designed for COVID-19, TNX-1840 and TNX-18505,

are live virus vaccines in development based on the RPV platform. Finally, TNX-35006 (sangivamycin, i.v. solution)

is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development.

1TNX-1500 is an investigational

new biologic at the pre-IND stage of development and has not been approved for any indication.

2TNX-102 SL is an investigational

new drug and has not been approved for any indication.

3TNX-1300 is an investigational

new biologic and has not been approved for any indication.

4TNX-801 is an investigational

new biologic at the pre-IND stage of development and has not been approved for any indication.

5TNX-1840 and TNX-1850 are

investigational new biologics at the pre-IND stage of development and have not been approved for any indication. TNX-1840 and TNX-1850

are designed to express the spike protein of SARS-CoV-2 from omicron and BA.2 variants, respectively, based on the experience from TNX-1800,

which expresses the spike protein from the ancestral Wuhan strain.

6TNX-3500 is an investigational

new drug at the pre-IND stage of development and has not been approved for any indication.

This press release and further information about Tonix

can be found at www.tonixpharma.com.

Forward-Looking Statements

Certain statements in this press release are

forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the

use of forward-looking words such as "anticipate," "believe," "forecast," "estimate,"

"expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations

and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those

indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA

clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks

related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties

of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development

efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant

risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update

or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year

ended December 31, 2020, as filed with the Securities and Exchange Commission (the "SEC") on March 15, 2021, and periodic

reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such

risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Jessica Morris (corporate)

Tonix Pharmaceuticals

Olipriya Das, Ph.D. (media)

Peter Vozzo (investors)